STOCK TITAN
  1. Home
  2. News
  3. RPTX

Repare Therapeutics Inc. Common Shares - $RPTX STOCK NEWS

Welcome to our dedicated page for Repare Therapeutics Common Shares news (Ticker: $RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics Common Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Repare Therapeutics Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Repare Therapeutics Common Shares's position in the market.

News
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
Rhea-AI Summary

Repare Therapeutics Inc. reported financial results for Q1 2024, highlighting clinical progress in various programs. FDA agrees with RP2D for lunresertib plus camonsertib combo. Phase 2 TRESR expansion and Phase 1 LIONS monotherapy trial initiated. $237.0M in cash to fund operations till mid-2026. Camonsertib rights regained, new trial initiations, and board appointment announced. Revenue from collaboration agreements increased to $52.4M. Net income for Q1 2024 was $13.2M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
Rhea-AI Summary

Repare Therapeutics and Debiopharm have dosed the first patient in the Phase 1/1b MYTHIC trial, evaluating the combination of PKMYT1 and WEE1 inhibition. This collaboration aims to assess safety, pharmacokinetics, and preliminary clinical activity of lunresertib and Debio 0123, showing promise for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
clinical trial
-
News
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
Rhea-AI Summary

Repare Therapeutics Inc. (Nasdaq: RPTX) appoints Dr. Steven H. Stein to its Board of Directors, thanking Todd Foley for his contributions. Dr. Stein brings extensive experience in oncology drug development, currently serving as the Chief Medical Officer of Incyte The Company looks forward to his guidance as it advances its precision oncology pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Repare Therapeutics Inc. announces participation in upcoming investor conferences to discuss precision oncology. Details include presentations at TD Cowen 44th Annual Healthcare Conference and Bloom Burton 2024 Healthcare Investor Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
conferences
-
News
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Repare Therapeutics Inc. reported financial results for Q4 and full year 2023, highlighting progress in their precision oncology programs. Key achievements include positive data from lunresertib trials, a partnership with Debiopharm, and a milestone payment from Roche. The company also disclosed plans for 2024, including new clinical trials and data readouts. Financially, Repare's cash position is strong, with $223.6 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
earnings
-
News
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
Rhea-AI Summary
Repare Therapeutics Inc. announces dosing of first patient in Phase 1 LIONS clinical trial for RP-1664, a potential first-in-class PLK4 inhibitor for solid tumors. RP-1664 shows promising tumor growth inhibition in TRIM37-high solid tumors and neuroblastoma models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
clinical trial
News
Repare Therapeutics to Regain Global Rights to Camonsertib
Rhea-AI Summary
Repare Therapeutics regains control of potential best-in-class oral small molecule ATR inhibitor, camonsertib, following termination of collaboration agreement with Roche. The company will now have full rights to develop and commercialize camonsertib, a promising precision oncology medicine that has shown clinical proof-of-concept in multiple tumor types and genotypes. Repare's deep clinical pipeline includes four wholly-owned synthetic lethal therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.58%
Tags
none
-
News
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
Rhea-AI Summary
Repare Therapeutics Inc. announced a $40 million milestone payment from Roche upon dosing of the first patient with camonsertib in Roche’s Phase 2 TAPISTRY trial. Repare is eligible to receive up to $1.2 billion in potential milestones, plus royalties on global net product sales. The collaboration also provides Repare with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
none
-
News
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) provides a corporate update and highlights key milestones anticipated in 2024. The company has advanced its pipeline significantly in 2023, presenting strong data from key programs such as lunresertib in combination with camonsertib, and camonsertib in combination with PARP inhibitors. Repare aims to expand its pipeline to four clinical-stage programs by the second half of 2024 and expects to share data readouts from ongoing studies of lunresertib combinations. The company also disclosed its partnership with Debiopharm to explore the potential clinical synergy of Debio 0123, a highly selective clinical WEE1 inhibitor, and lunresertib. Additionally, Repare announced key milestones anticipated in 2024, including the initiation of several Phase 1 studies and the reporting of data from ongoing studies. The company ended 2023 with approximately $223 million in cash, cash equivalents, and marketable securities, which is anticipated to fund planned operations into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.32%
Tags
none
News
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) collaborates with Debiopharm to investigate the combination of lunresertib, a PKMYT1 inhibitor, and Debio 0123, a WEE1 inhibitor, in a new arm of Repare’s ongoing global MYTHIC study. The Phase 1/1b clinical trial is anticipated to initiate in the first half of 2024. The collaboration aims to explore the synergy between the two compounds and share all costs equally. The combination has shown highly synergistic and promising preclinical data, demonstrating potential transformative benefit to patients with high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
partnership
Stock RPTX logo
Repare Therapeutics Inc. Common Shares

Nasdaq:RPTX

RPTX Rankings

#3960 Ranked by Market Cap
#5284 Ranked by Stock Gains
N/A Ranked by Dividends

RPTX Stock Data

160.87M
14.92M
1.02%
94.48%
1.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAINT-LAURENT

About RPTX

repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.